Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open-label phase II prospective trial

Hidradenitis suppurativa Research

Author(s): Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A, Giamarellos-Bourboulis EJ

OBJECTIVE: To evaluate the long-term efficacy of etanercept for the management of hidradenitis suppurativa.

METHODS: Analysis was based on the long-term follow-up (weeks 24-144) of 10 patients enrolled in a prospective open-label phase II study; etanercept was initially administered subcutaneously 50 mg once weekly for 12 weeks in 10 patients. Disease recurrence and the need to restart etanercept were recorded.

RESULTS: Three patients did not report any disease recurrence. A second course of treatment with etanercept was needed in seven patients. Favourable responses were found in five; two patients failed treatment.

CONCLUSIONS: The first treatment course achieved long-term disease remission in almost one-third of patients. The remaining needed a second treatment course but even in that case, their disease severity at restart was significantly lower compared with baseline.

Dermatology Journal and/or Publisher

Journal Name: Experimental dermatology
Journal Abbreviation: Exp. Dermatol.
Journal Date Published: 2010-06-29

National Center for Biotechnology Information

PMID: 19758320
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/19758320
Lasted Revision: 2015-11-19

Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).


Leave a reply

HSAWARENESS.ORG | Fighting for Hidradenitis suppurativa (HS), a.k.a Acne Inversa Patient and Doctor Awareness ©2018 hidradenitissuppurativaawareness.org  All Rights Reserved. Your use of this website constitutes explicit agreement to our Terms of Use and Privacy Policies. This website does not provide medical advice, diagnosis or treatment.

Log in with your credentials

Forgot your details?